Pulmatrix Terminates Planned Merger with Cullgen, Pursues Alternative Opportunities

Pulmatrix announced that Cullgen Inc. has terminated their planned merger, citing lack of approval from the China Securities Regulatory Commission. Despite this setback, Pulmatrix is continuing to pursue alternative merger opportunities. The company remains focused on developing inhaled therapeutic products using its patented iSPERSE technology to prevent and treat migraine and respiratory diseases.